نتائج البحث

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

• Authors : Alliance Foundation Trials, LLC.; NSABP Foundation Inc

• Source: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual

تفاصيل العنوان

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

• Source: A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual

تفاصيل العنوان

Tissue Models for Invasive Disease (TIMID) (TIMID)

• Authors : University Hospitals, Leicester; University of Nottingham

• Source: TIssue Models for Invasive Disease (TIMID)Carreno D, Wanford JJ, Jasiunaite Z, Hames RG, Chung WY, Dennison AR, Straatman K,

تفاصيل العنوان

Invasive Disease Caused by Group A Streptococcus (GAS) (DICAR) (DICAR)

• Authors : Turku University Hospital; University of Turku; Ville Kaila, Clinical investigator

• Source: Invasive Disease Caused by Group A Streptococcus (GAS) - a Prospective Study (DICAR)

تفاصيل العنوان

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

• Authors : Roche Pharma AG

• Source: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive

تفاصيل العنوان

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2) (EXPECT-2)

• Authors : Janssen Research & Development, LLC; Innovative Medicines Initiative; MJM Bonten, Professor of Molecular Epidemiology of Infectious Diseases

• Source: Prospective Epidemiological Study to Estimate the O-serotype Distribution of Extraintestinal Pathogenic Escherichia Coli (ExPEC) Isolated From Hospitalized Patients Aged 60 Years or Older With

تفاصيل العنوان

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1) (EXPECT-1)

• Authors : Janssen Research & Development, LLC; Innovative Medicines Initiative; MJM Bonten, Professor doctor

• Source: Pilot Study to Assess Success Factors and Barriers for Preparation of a Phase 3 Study With ExPEC10V in Adults Aged 60 Years or Older and in Stable Health

تفاصيل العنوان

Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (FinIP)

• Source: Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive DiseasePalmu AA, Jokinen J,

تفاصيل العنوان

A Study of Streptococcus Pneumonia Colonisation and Invasive Disease in Cambodian Children (PCV)

• Source: Monitoring Pneumococcal Conjugate Vaccine Introduction in Cambodia: A Study of Streptococcus Pneumoniae Colonisation, Pneumonia and Invasive

تفاصيل العنوان

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

• Authors : Daiichi Sankyo; SWOG Clinical Trials Partnerships

• Source: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer

تفاصيل العنوان